Mortality analysis of patients taking less than 6 boxes and more than 6 boxes: All the cases investigated in this paper had a life span of 10/9 people as of October 30th, 2004, among whom the oldest was 76 years old and the youngest was 14 years old. 76 of them survived and 43 died. See table 1 for the usage of this product. Table 1 analysis 1 19 cases of primary brain tumor treated with this product, overall survival and death.
The classification and treatment of 56 patients with brain tumors who lived in 6 boxes or more using this product were analyzed. The results are shown in Table 2: Table 2 Analysis of 56 patients with brain tumor who used this product and lived in 6 boxes or more. The average age of men and women is the pituitary tumor mother of glioma.
Cell tumor hand
Surgical release
therapy
Treat others
Traditional Chinese medicine 56 34 22 45.4 565 438+0 465 438+0 38 265 438+0 85 rate% 60.7 39.391.171867.9 37.514.38.9 from table 2. Female, with an average age of 45.4 years, tends to be younger. Most of them were gliomas, and 38 cases were treated by surgery, accounting for 67.9% of the total number of patients treated. Most patients received postoperative radiotherapy (including gamma knife therapy), and 265,438+0 cases were treated with this product. Other treatments account for a small proportion. Among them, 38 cases underwent one operation and no second operation.
The changes of brain tumor and its condition were analyzed in 56 patients who survived taking 6 or more boxes of this product. The results are shown in Table 3. Table 3 Analysis of Tumor Changes and Disease Changes
No tumor.
The condition is stable and the tumor recurs.
The tumor recurred and transformed well.
The tumor turned stable and was not examined.
No stable tumor was examined.
The state is relatively stable, and there is no inspection.
Recurrence of poor condition
Turn cerebellum to suffer from other diseases
Encephalopathy 56 36 3 5 4 2 1 2 has always existed.
The effective rate was 5 1/56=9 1.07%, that is, the brain tumor did not change or grow after operation, and there was no obvious discomfort, especially the symptoms of intracranial hypertension such as headache, vomiting, tumor compression and convulsion. If you take this product intermittently, you can live and do social and housework like a normal person; The condition is relatively stable, which means that there are occasional symptoms of brain tumors such as headache, dizziness and no convulsions. And the tumor has no change after taking this product intermittently, or the tumor has no aging after operation; Poor condition refers to uncontrolled tumor, frequent brain tumor compression, different degrees of limb and language disorders, of which 1 case has confusion. In Table 3, due to financial constraints, two patients only took this product for one course of treatment, and then they could not continue treatment. 1 case was not examined after operation, but the condition worsened. 1 case was not operated, and the condition was serious at the time of seeing a doctor. As can be seen from Table 3, 5 1 patient with stable or relatively stable condition should be regarded as effective after reexamination, and the effective rate is 9 1.07%. These patients have taken this product intermittently, and the symptoms of various brain tumors have been significantly improved, and some have also engaged in some housework and social work.
Life statistics. The life span is calculated in person years, and if a person lives 18 months, it is 1.5 person years [*]. Table 4 shows the survival years of 56 patients studied in this paper. Table 4 Analysis of life span of 56 patients with brain tumor with this product ≥6 boxes: reciprocal 18.58-8 person-years 7.92-5 person-years 4.92-3 person-years 2.92- 1 0.92 person-years 5658/3291average person-years = 3. Among them, 1 patients have survived for more than 18.5 person-years, and now they take this product intermittently without any discomfort and are engaged in business work. The average survival time of 26 patients who survived for more than 3 years was 5.7 years. In other words, among the 56 patients surveyed, 46.4% lived for more than 5.7 years. This may be an amazing number. Because of the short onset period, the survival time of patients who developed the disease after 2002 is less than 3 person-years. An average of 3.4 person-years is greatly affected by this. According to the investigation in, it can be considered that the effect of this product in the treatment of primary brain tumor increases significantly with the increase of dose. Taking this product to treat brain tumors greatly improves the survival time and quality of life of patients with brain tumors.
conclusion
Selenium-enriched Lingzhibao is a scientific mixture of biotransformation selenium protein and wall-broken ganoderma lucidum spore powder, which can inhibit the growth of tumor cells, cooperate with radiotherapy and chemotherapy, reduce toxicity and increase efficiency, prevent tumor recurrence and metastasis, and improve immunity. From the survey of 1 19 patients who took this product, it is proved that the curative effect cannot be estimated after taking this product for less than one course of treatment. 17 More than 6 boxes of this product were used in the dead patients, and the dosage was only in one course of treatment (6 boxes), but not more than 3 courses of treatment. Among the 56 surviving patients, the most was 69 boxes (. Because this product can penetrate the blood-brain barrier, it has special effects on treating brain tumors, especially brain malignant tumors. The total effective rate is 9 1.07%, especially for patients with postoperative recurrence. After taking this product, the development of the disease is controlled. 1 glioma patients 1998 surgery, 200 1 tumor recurrence. Without surgery, the condition deteriorated seriously, and serious symptoms such as limb, language, thinking disorder and headache appeared due to tumor compression. They started taking this product in May, 20001year. After two courses of treatment, the convulsions and vomiting stopped. Up to now, the condition has been stable for 3 years, and the product is taken every spring and autumn 1-2 courses.
This product can treat pituitary adenoma and effectively control the growth of pituitary adenoma. Only 1 case of pituitary adenoma was operated, and the other 3 cases were treated conservatively without radiotherapy and chemotherapy. All four patients had different degrees of visual impairment. After taking this product, the tumor did not develop again, and their physical and mental state was good, and they could maintain a normal life. According to the survey in this paper, more than 95% patients with brain tumors recognize the efficacy of this product, but some patients can not take it continuously or in spring and autumn due to economic constraints. Seriously affected the effect of this product in treating brain tumors.
refer to
* Fang Jigan, Health Statistics, August 2003, P33 1-333. Key words: primary liver cancer, metastatic cancer
Selenium-enriched Lingzhibao (hereinafter referred to as this product)
Course of treatment (30 days is a course of treatment)
Source and Method: Source: (1) Se-enriched Lingzhibao: developed by China Academy of Agricultural Sciences, approved by People's Republic of China (PRC) and Ministry of Health, and produced by Beijing Ruiye Pharmaceutical Co., Ltd.
⑵ Source of patients: This article was collected from July 2000 to June 2003 at 365438+February 3 1, and the survival time and death date were June 365438+1October 3 1, 2004. 469 cases of primary liver cancer were treated with selenium-enriched Lingzhibao in Shenyang market, of which 66 cases survived/kloc-0 and 303 cases died.
⑶ Administration method: Generally, patients take 2g every morning, before meals 1 hour, and take it with boiling water every 30 days. If the condition is serious, the dosage can be increased appropriately.
Methods: (1) 356 patients who used this product for less than 2 courses of treatment, including 96 survivors and 260 dead patients.
⑵ 1 13 patients used this product for two or more courses, including 70 survivors and 43 dead patients.
The data of ⑤ and ⑤ groups were analyzed to test the significance of treatment effect between groups.
⑶ 70 patients who survived for more than 2 courses were analyzed and the therapeutic effect of this product was evaluated.
Results the mortality of patients with primary liver cancer who took this product for less than 2 courses and more than 2 courses was analyzed. The results are shown in table 1. As can be seen from the table 1, 356 patients were treated with this product for less than 2 courses, of which 260 patients died and 96 survived, with a mortality rate of 73.03%. 1 13 patients used this product for two or more courses of treatment, among which 43 patients died and 70 survived, with a mortality rate of 38.05%. After statistical processing, P
The survival time of 70 patients with primary liver cancer who survived for more than 2 courses was studied. The results are shown in Table 3. Table 3: The life years of 70 patients who survived after two courses of treatment with this product were investigated.
1993199519961999 2000 2006 5438+0 2002 2003 total average.
The annual population is11123123 29 70 sick -2004. 10 average.
survive
Man-year11.33 9.50 8.42 5.044.143.352.161.432.52 Man-year.
× number of people = total person years11.33 9.50 8.4210.0812.43 33.49 49.6641.60176.5/kloc-. The situation is stable at present. Three people survived for more than 8.4 years, and five people survived for more than 5 years. Since the product went on the market, 65,438+08 people have received the combined treatment of this product and other methods, and the survival time has exceeded 3.3 years. The number of people whose survival time is more than 2. 1 year is 5 1, accounting for 72.9% of the total number.
The treatment and condition analysis of 70 patients with primary liver cancer who survived for more than 2 courses using this product are shown in Table 4. Table 4 Treatment and condition analysis of 70 patients who survived more than 2 courses of treatment with this product.
Average number of men and women
Age hand
Surgical release
chemotherapy
include
Intervene in cooperation
other
Average dosage of this product
Treatment conditions
stationary state
in order
stationary state
Bad 70511962.21321224.5632317 rate%15.74.330.03144366. The average course of treatment of this product is 4.56. Some patients received radiotherapy, chemotherapy and surgery. Cooperating with other drugs refers to people who have used other anticancer drugs or Chinese and western medicines. Patients with stable condition and good condition refer to: the tumor shrinks or remains unchanged, all kinds of discomfort disappear, and they can live like normal people. Of the 32 people, 3 have gone to work normally and 2 have traveled abroad. There are 3 1 patient whose condition is relatively stable: the tumor is not large, has not metastasized, and is slightly unwell. Under these two conditions, some patients still insist on intermittent use of this product or use it in spring and autumn every year for 1-2 courses. Both of them should be effective with this product, accounting for 90% of the total. Seven patients were in poor condition, referring to tumor growth or metastasis, ascites and edema in different degrees, and pain in liver area.
The specific conditions of 32 patients in good condition and 7 patients in poor condition were analyzed, and the results are shown in Table 5. Table 5 Survey scores of patients with primary liver cancer in good state and bad state
Group example
Turnover years
move
liver
Cancerous liver
turn
Fermi
flood
liver
Cancer radiation
therapy
Hand therapy
Shu Qi; Hsu Kei、Hsu Chi
it
medical science
product
match
Combined use
This product
Average
2000 course of treatment
Previously 0 1
In 2002
In 2003
The annual status is good: 323141331128795.69.
Bad 70007112022.71As can be seen from Table 5, among 32 patients in good condition, 7 patients underwent surgery and 8 patients underwent chemotherapy, and then they were treated with this product. The general course of treatment is about 6 courses, which is more than twice that of poor conditions. None of the 7 patients in poor condition underwent surgery. These patients came to the hospital in 2003. Generally, they are in the late stage when they see a doctor, and rarely cooperate with other treatments. Some patients have metastasis, ascites and liver pain. Lose the chance of surgery. Treatment with this product can prolong life.
Among the surviving patients, 32 cases were in good condition, 365,438+0 cases were stable, and 7 cases were in poor condition. The results are shown in Table 6. Table 6 The relationship between operation and recovery of 70 patients with primary liver cancer treated with this product for ≥2 courses. The condition is good and the condition is relatively stable. The total operative rate was% 74 01115.7, 25 27 759, which was 32 317 70. As can be seen from Table 6, among 70 patients treated with this product for 2 or more courses, 4 patients were in stable condition after operation, and the bad situation was 0. After chi-square (x) test, the difference of counting data was not significant (P > 0.05). Other drugs such as radiotherapy and chemotherapy have no statistical significance. It shows that among the 70 patients investigated in this paper, there is no significant difference in drug treatment such as surgery, radiotherapy and chemotherapy.
After using this product for ≥2 courses, the tumor changes of 70 patients are shown in Table 7. Table 7 Among the 70 patients who survived after more than 2 courses of treatment with this product, the number of cases of tumor change analysis disappeared and decreased.
1/2- 1/3 tumor
Slightly reduced tumor
Late stage of stable metastasis
Unchecked tumor
Grow up 70 271135122 rate% 2.8610.0015.75438+0 50.0010.4317. Among the patients who took this product for two or more courses, 2 patients' tumors disappeared, 7 patients' tumors shrank 1/2- 1/3, accounting for 10% of the total, and 50% patients' tumors did not change much. Tumor control accounted for 78.6% of the total. Some patients were not reexamined in the later period. Tumor growth occurred in 2 cases (2.86%). When these two patients came to see a doctor, it was already late. The product controls diseases, prolongs life and improves quality of life.
Discussion Liver cancer (mainly primary liver cancer) is one of the common diseases in China and Asia, and its incidence ranks third among malignant tumors in China. There are about hundreds of thousands of new cases every year. This disease is more common in middle-aged and elderly men. The onset of the disease is hidden, and the early symptoms are usually only nonspecific symptoms such as fatigue, loss of appetite, abdominal distension and emaciation. Many patients are in the advanced stage when they see a doctor, and they have lost the opportunity of surgery.
Studies have shown that human cancer is closely related to selenium deficiency. Because the intake of selenium is low, the blood selenium content is low. People with low blood selenium level have high cancer incidence and mortality. At present, selenium supplementation has successfully prevented and treated cancer on a large scale. Some people compare the first-degree relatives of families with high incidence of primary liver cancer with those without selenium supplement. The incidence of primary liver cancer in the former is 2.5 times lower than that in the control group, and the liver and kidney function of the experimenter has no adverse effect, which shows that selenium supplementation is safe and reliable for cancer prevention. [ 1]
With the development of science and technology, the treatment of cancer has made great progress. "Selenium-enriched Lingzhibao" developed by China Academy of Agricultural Sciences, in which "selenium" is a biotransformed organic selenium protein, has high absorption rate and has no toxic and side effects on human body. "Ganoderma lucidum" refers to the broken wall of Ganoderma lucidum spore powder, which is combined by scientific proportion and specific technical means. "Selenium" can inhibit the growth of cancer cells by increasing the level of cyclic adenosine monophosphate (cAMP) and forming an internal environment that inhibits the division and proliferation of cancer cells. [2] Under the same conditions, selenium has a certain protective effect on non-cancer cells. Wall-broken ganoderma lucidum spore powder can increase immunoglobulin (antibody) content and enhance phagocytosis. The "Se-enriched Lingzhibao" combined with the two can directly kill cancer cells and obviously improve physical strength, appetite, sleep and disease resistance. The tumor was suppressed and shrunk. Since 1999 went on the market, this product has been favored by cancer patients.
In this paper, only from July 2000 to February 3, 20031(the statistical date was June 65438+1October 3, 20041), 469 patients with primary liver cancer were treated and the relevant data were analyzed. As can be seen from the survey and statistical results in this paper:
Selenium-enriched Lingzhibao is effective in treating primary liver cancer. But the dosage should exceed 5-6 courses of treatment. After 2 courses of treatment, the therapeutic effect of this product cannot be evaluated. As can be seen from Table 2 above, patients in good and stable condition should be regarded as effective after taking this product. The total effective rate of patients who take this product for about 5 courses is 90%, which is difficult to be achieved by general anticancer drugs. Even for patients with advanced primary liver cancer, taking this product only lasted for about 3 courses, which also prolonged the survival time. Among 7 patients with severe liver cancer, all occurred in 2003, the earliest in April 2003 and the latest in September 2003. The average survival time has exceeded one and a half years, and it is still alive today. Generally, it is difficult for patients with advanced stage to survive for more than half a year. Relationship between primary liver cancer and surgical treatment. Generally, the combination of radiotherapy and chemotherapy after early primary liver cancer surgery can reduce the toxic and side effects of radiotherapy and chemotherapy, increase the curative effect and quickly restore physical fitness. Of the 70 patients studied in this paper, only 3 patients were treated with this product through surgery combined with chemotherapy. One of the patients, a 54-year-old male, was diagnosed with primary liver cancer in August 2002 and received chemotherapy after operation. I'm in good shape now. However, there are few surgical cases investigated in this paper, and there is no significant difference between surgery and single use of this product. Discussion on survival time of patients with primary liver cancer. People's life span is measured in years. If a person's survival time is 1 year for 4 months, then his survival time is 1.33 person-years, that is, 1.3 person-years [3]. In this paper, among 70 patients who used this product for two or more courses, 18 patients survived for more than 3.3 person-years, with an average survival time of 2.5 person-years. This result is quite gratifying. Patient Liu XX, female, 48 years old, became ill in May 1996. After the operation, she did not receive radiotherapy and chemotherapy. After the product was put on the market, she used this product to consolidate the treatment. Her life span has exceeded 8.4 person-years, and she has no discomfort at present and has gone to work. Patient Teng X, female, 65 years old, developed symptoms from June, 5438 to October, 2000/kloc-0. At that time, the hospital told her family that the patient's survival time was only about 30 days. The patient's primary liver cancer was advanced and could not be operated and treated with radiotherapy and chemotherapy. After three courses of treatment, the tumor shrank 1/3, and all the symptoms improved. After taking this product intermittently, the survival time has been 4 years, and the liver has no discomfort. Obviously, if this product is used to treat primary liver cancer for more than 2 courses, the survival time of patients will be greatly improved.
Because the patients surveyed in this paper received less drugs such as radiotherapy and chemotherapy, it was not significant after statistical treatment. The curative effect of this product combined with radiotherapy, chemotherapy and other drugs on primary liver cancer needs to be further determined. refer to
[1] Li Yuanguang et al., 1992, supplement of trace elements and health research, 16- 19.
[2] Yu Shuyu et al., 1983, Journal of China Academy of Medical Sciences, Vol.5, No.3, 196- 198.
[3] Fang, August 2003, Health Statistics, 5th Edition, 33 1-333.